In vitro synergistic activity of tigecycline and colistin against XDR-Acinetobacter baumannii

被引:42
作者
Dizbay, Murat [1 ]
Tozlu, Derya Keten [1 ]
Cirak, Meltem Yalinay [2 ]
Isik, Yasemin [2 ]
Ozdemir, Kevser [1 ]
Arman, Dilek [1 ]
机构
[1] Gazi Univ, Sch Med, Dept Clin Microbiol & Infect Dis, TR-06510 Ankara, Turkey
[2] Gazi Univ, Sch Med, Dept Microbiol & Clin Microbiol, TR-06510 Ankara, Turkey
关键词
Acinetobacter baumannii; colistin; combination; rifampin; synergy; tigecycline; ANTIMICROBIAL SUSCEPTIBILITY; NOSOCOMIAL INFECTIONS; DRUG-RESISTANT; COMBINATION; STRAINS; PCR;
D O I
10.1038/ja.2009.117
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The emergence of extensive drug-resistant (XDR) Acinetobacter baumannii limits the therapeutic options and leads to high mortality in intensive care units. Combined antibiotic therapy is frequently recommended for the treatment of these infections. Colistin (CO) and tigecycline (TIG), alone or in combination with other antimicrobials, are the most commonly used antibiotics in the treatment of these resistant infections. In this study, the in vitro synergistic activity of TIG and CO were tested for 25 XDR-A. baumannii strains isolated from ventilator-associated pneumonia by the Etest method. Resistance to CO was not detected, whereas 8% of the strains were resistant to TIG. The TIG-CO combination was more synergistic than TIG-rifampin and CO-rifampin according to the fractional inhibitory concentration index. No antagonism was detected between the drugs in the study. There was no strong correlation between the activity of the combinations with reference to strains or genotypes. Our results suggest that the combined use of TIG and CO may be useful for the treatment of XDR-A. baumannii infections. The Journal of Antibiotics (2010) 63, 51-53; doi:10.1038/ja.2009.117; published online 27 November 2009
引用
收藏
页码:51 / 53
页数:3
相关论文
共 24 条
[1]  
Clinical and Laboratory Standards Institute, 2007, M100S17 CLSI S
[2]   Colistin and tigecycline susceptibility among multidrug-resistant Acinetobacter baumannii isolated from ventilator-associated pneumonia [J].
Dizbay, M. ;
Altuncekic, A. ;
Sezer, B. Ergut ;
Ozdemir, K. ;
Arman, D. .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2008, 32 (01) :29-32
[3]  
DIZBAY M, 2008, J ANKEM, V22, P28
[4]   Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia [J].
Fritsche, TR ;
Sader, HS ;
Stilwell, MG ;
Dowzicky, MJ ;
Jones, RN .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2005, 52 (03) :187-193
[5]   Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: Review of available interpretative criteria and quality control guidelines [J].
Gales, AC ;
Reis, AO ;
Jones, RN .
JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (01) :183-190
[6]   Acinetobacter baumannii:: a universal threat to public health? [J].
Giamarellou, Helen ;
Antoniadou, Anastasia ;
Kanellakopoulou, Kyriaki .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2008, 32 (02) :106-119
[7]  
Hsueh PR, 2002, EMERG INFECT DIS, V8, P827
[8]   Colistin as a salvage therapy for nosocomial infections caused by multidrug-resistant bacteria in the ICU [J].
Kallel, Hatem ;
Bahloul, Mabrouk ;
Hergafi, Leila ;
Akrout, Malek ;
Ketata, Wajdi ;
Chelly, Hedi ;
Ben Hamida, Chokri ;
Rekik, Noureddine ;
Hammami, Adnane ;
Bouaziz, Mounir .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2006, 28 (04) :366-369
[9]   Antibiotic resistance surveillance over a 4-year period (2000-2003) in Turkey: results of the MYSTIC Program [J].
Korten, Volkan ;
Ulusoy, Sercan ;
Zarakolu, Pinar ;
Mete, Birgul .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2007, 59 (04) :453-457
[10]   Treatment of pan-drug resistant Acinetobacter baumannii [J].
Lee, CM ;
Lim, HK ;
Liu, CP ;
Tseng, HK .
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2005, 37 (03) :195-199